Hepatología: Metabolismo, Epigenética y Carcinogénesis
METACAN
Instituto de Investigación Sanitaria Biogipuzkoa
San Sebastián, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria Biogipuzkoa (6)
2024
-
MCPIP1 Inhibits Hepatic Stellate Cell Activation in Autocrine and Paracrine Manners, Preventing Liver Fibrosis
Cellular and Molecular Gastroenterology and Hepatology, Vol. 17, Núm. 6, pp. 887-906
2022
-
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming
Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1
-
Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models
Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190
2021
-
FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted
Journal of Hepatology, Vol. 75, Núm. 2, pp. 363-376
2014
-
Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases
Gut, Vol. 63, Núm. 10, pp. 1658-1667
-
Matrix metalloproteinase-10 expression is induced during hepatic injury and plays a fundamental role in liver tissue repair
Liver International, Vol. 34, Núm. 7